tonix pharmaceuticals holding corp - TNXP
TNXP
Close Chg Chg %
15.82 -0.19 -1.18%
Open Market
15.63
-0.19 (1.18%)
Volume: 292.77K
Last Updated:
Dec 31, 2025, 1:14 PM EDT
Company Overview: tonix pharmaceuticals holding corp - TNXP
TNXP Key Data
| Open $15.80 | Day Range 15.50 - 16.11 |
| 52 Week Range 6.76 - 69.96 | Market Cap $202.31M |
| Shares Outstanding 12.79M | Public Float 12.78M |
| Beta 1.83 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$986.99 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 545.15K |
TNXP Performance
| 1 Week | -2.71% | ||
| 1 Month | -0.94% | ||
| 3 Months | -34.08% | ||
| 1 Year | -52.03% | ||
| 5 Years | N/A |
TNXP Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About tonix pharmaceuticals holding corp - TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
TNXP At a Glance
Tonix Pharmaceuticals Holding Corp.
26 Main Street
Chatham, New Jersey 07928
| Phone | 1-862-799-8599 | Revenue | 10.09M | |
| Industry | Pharmaceuticals: Major | Net Income | -130,036,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 29.943% | |
| Fiscal Year-end | 12 / 2025 | Employees | 81 | |
| View SEC Filings |
TNXP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.024 |
| Price to Book Ratio | 0.01 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.217 |
| Enterprise Value to Sales | -8.957 |
| Total Debt to Enterprise Value | -0.09 |
TNXP Efficiency
| Revenue/Employee | 124,617.284 |
| Income Per Employee | -1,605,382.716 |
| Receivables Turnover | 1.277 |
| Total Asset Turnover | 0.064 |
TNXP Liquidity
| Current Ratio | 6.50 |
| Quick Ratio | 6.041 |
| Cash Ratio | 5.396 |
TNXP Profitability
| Gross Margin | -10.818 |
| Operating Margin | -770.20 |
| Pretax Margin | -1,288.25 |
| Net Margin | -1,288.25 |
| Return on Assets | -81.952 |
| Return on Equity | -106.116 |
| Return on Total Capital | -88.054 |
| Return on Invested Capital | -101.077 |
TNXP Capital Structure
| Total Debt to Total Equity | 5.818 |
| Total Debt to Total Capital | 5.498 |
| Total Debt to Total Assets | 4.984 |
| Long-Term Debt to Equity | 3.601 |
| Long-Term Debt to Total Capital | 3.403 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tonix Pharmaceuticals Holding Corp - TNXP
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 7.77M | 10.09M | - |
Sales Growth
| - | - | - | +29.94% | - |
Cost of Goods Sold (COGS) incl D&A
| 50.00K | 1.25M | 9.03M | 11.19M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 50.00K | 1.25M | 4.29M | 3.42M | |
Depreciation
| - | 1.25M | 4.29M | 2.95M | |
Amortization of Intangibles
| - | - | - | 476.00K | - |
COGS Growth
| +85.19% | +2,406.00% | +620.83% | +23.85% | |
Gross Income
| (50.00K) | (1.25M) | (1.26M) | (1.09M) | |
Gross Income Growth
| -85.19% | -2,406.00% | -0.88% | +13.61% | |
Gross Profit Margin
| - | - | -16.27% | -10.82% | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 92.26M | 110.84M | 117.12M | 76.65M | |
Research & Development
| 68.84M | 81.88M | 86.66M | 39.97M | |
Other SG&A
| 23.42M | 28.96M | 30.46M | 36.68M | |
SGA Growth
| +82.75% | +20.13% | +5.66% | -34.55% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (300.00K) | 52.81M | - |
EBIT after Unusual Expense
| (92.31M) | (112.09M) | (118.08M) | (130.55M) | |
Non Operating Income/Expense
| 25.00K | 1.87M | 1.42M | 515.00K | |
Non-Operating Interest Income
| - | - | 25.00K | 1.87M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (92.29M) | (110.22M) | (116.66M) | (130.04M) | |
Pretax Income Growth
| -82.88% | -19.43% | -5.84% | -11.47% | |
Pretax Margin
| - | - | -1,501.78% | -1,288.25% | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (92.29M) | (110.22M) | (116.66M) | (130.04M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (92.29M) | (110.22M) | (116.66M) | (130.04M) | |
Net Income Growth
| -82.88% | -19.43% | -5.84% | -11.47% | |
Net Margin Growth
| - | - | -1,501.78% | -1,288.25% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (92.29M) | (110.22M) | (116.66M) | (130.04M) | |
Preferred Dividends
| - | - | - | 6.66M | - |
Net Income Available to Common
| (92.29M) | (116.88M) | (116.66M) | (130.04M) | |
EPS (Basic)
| -163968 | -65405.8 | -21908.48 | -17659.801 | |
EPS (Basic) Growth
| +53.55% | +60.11% | +66.50% | +19.39% | |
Basic Shares Outstanding
| 562.8364421900001 | 1.79K | 5.32K | 7.36K | |
EPS (Diluted)
| -163968 | -65405.8 | -21908.48 | -17659.801 | |
EPS (Diluted) Growth
| +53.55% | +60.11% | +66.50% | +19.39% | |
Diluted Shares Outstanding
| 562.8364421900001 | 1.79K | 5.32K | 7.36K | |
EBITDA
| (92.26M) | (110.84M) | (114.09M) | (74.32M) | |
EBITDA Growth
| -82.75% | -20.13% | -2.93% | +34.86% | |
EBITDA Margin
| - | - | -1,468.70% | -736.31% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 64.50 | |
| Number of Ratings | 2 | Current Quarters Estimate | -2.575 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -7.797 | |
| Last Quarter’s Earnings | -2.98 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -13.43 | Next Fiscal Year Estimate | -3.09 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 3 | 2 |
| Mean Estimate | -2.58 | -2.27 | -7.80 | -3.09 |
| High Estimates | -2.55 | -2.25 | -6.78 | -1.08 |
| Low Estimate | -2.60 | -2.29 | -8.60 | -5.10 |
| Coefficient of Variance | -1.37 | -1.25 | -11.91 | -91.99 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Tonix Pharmaceuticals Holding Corp - TNXP
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tonix Pharmaceuticals Holding Corp - TNXP
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 3, 2025 | Adeoye Y. Olukotun Director | N/A | Other acquisition or disposition Non-derivative transaction at $1.91 per share | 0.00 |
| Mar 3, 2025 | Jamie D. Treco Director | N/A | Other acquisition or disposition Non-derivative transaction at $0.3 per share | 0.00 |
| Mar 3, 2025 | Richard H. Bagger Director | N/A | Other acquisition or disposition Non-derivative transaction at $0.2 per share | 0.00 |
| Mar 3, 2025 | Margaret Smith Bell Director | N/A | Other acquisition or disposition Non-derivative transaction at $0.15 per share | 0.00 |
| Feb 28, 2025 | Siobhan Fogarty Chief Technology Officer | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Siobhan Fogarty Chief Technology Officer | 13,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Bradley Saenger Chief Financial Officer | 25,792 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Bradley Saenger Chief Financial Officer | 25,792 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Bradley Saenger Chief Financial Officer | N/A | Other acquisition or disposition | 0.00 |
| Feb 28, 2025 | Gregory W. Sullivan Chief Medical Officer | 29,017 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Gregory W. Sullivan Chief Medical Officer | 29,017 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Gregory W. Sullivan Chief Medical Officer | N/A | Other acquisition or disposition Non-derivative transaction at $1.47 per share | 0.00 |
| Feb 28, 2025 | Seth Lederman Chief Executive Officer; Director | 123,958 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Seth Lederman Chief Executive Officer; Director | 123,958 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Seth Lederman Chief Executive Officer; Director | N/A | Other acquisition or disposition Non-derivative transaction at $0.15 per share | 0.00 |
| Feb 28, 2025 | Seth Lederman Chief Executive Officer; Director | 1 | Other acquisition or disposition Non-derivative transaction at $3.3 per share | 3.30 |
| Feb 28, 2025 | Seth Lederman Chief Executive Officer; Director | 5 | Other acquisition or disposition Non-derivative transaction at $3.38 per share | 16.90 |
| Feb 28, 2025 | Jessica Edgar Morris Chief Operating Officer | 29,291 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Jessica Edgar Morris Chief Operating Officer | 29,291 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2025 | Jessica Edgar Morris Chief Operating Officer | N/A | Other acquisition or disposition | 0.00 |